News
FRNM
12.77
-2.52%
-0.33
Freenome rallies after launching lung cancer screening blood test
TipRanks · 3d ago
Freenome Expands Cancer Screening with SimpleScreen Lung Launch
TipRanks · 3d ago
Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
Benzinga · 3d ago
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Seeking Alpha · 4d ago
Weekly Report: what happened at FRNM last week (1012-1016)?
Weekly Report · 4d ago
Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought Instead
TipRanks · 10/13 09:45
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Seeking Alpha · 10/12 11:05
Weekly Report: what happened at FRNM last week (1005-1009)?
Weekly Report · 10/12 10:35
Freenome Highlights Improved SimpleScreen CRC Performance Data At ACG 2026; Stock Up
NASDAQ · 10/12 07:17
Freenome To Present Improved Precancerous Lesion Detection Data For CRC Blood Test
NASDAQ · 10/12 04:52
Freenome to present new data on updated version of SimpleScreen CRC
TipRanks · 10/11 18:50
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Benzinga · 10/06 15:46
Weekly Report: what happened at FRNM last week (0928-1002)?
Weekly Report · 10/05 10:34
Weekly Report: what happened at FRNM last week (0921-0925)?
Weekly Report · 09/28 10:28
GRAIL sets new 52-week high as FDA panel backs cancer test
Seeking Alpha · 09/24 15:56
Grail panel votes ‘closer than we expected,’ says BTIG
TipRanks · 09/24 13:36
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Seeking Alpha · 09/22 16:24
Biotech Stocks At 52-Week Highs - HSCS +7%, FRNM +5%, VOGX, HTFL, HALO
NASDAQ · 09/21 13:35
Weekly Report: what happened at FRNM last week (0914-0918)?
Weekly Report · 09/21 10:29
Weekly Report: what happened at FRNM last week (0907-0911)?
Weekly Report · 09/14 10:34
More
Webull provides a variety of real-time FRNM stock news. You can receive the latest news about Freenome, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About FRNM
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.